Denali Therapeutics Inc (DNLI) Q3 2026 Earnings Call Highlights: AVLAYAH Revenue Soars Nearly ...
Denali Therapeutics Inc (DNLI) beat Q3 revenue guidance on rapid payer coverage gains and faster patient transitions, guided Q4 to $30--32 million, and ended the quarter with $1.01 billion in cash. Related Stocks: DNLI ,